Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Research article

Long-term impact of baseline serum uric acid levels on living kidney donors: a retrospective study

Authors: Kosuke Tanaka, Shigeyoshi Yamanaga, Yuji Hidaka, Sho Nishida, Kohei Kinoshita, Akari Kaba, Toshinori Ishizuka, Satoshi Hamanoue, Kenji Okumura, Chiaki Kawabata, Mariko Toyoda, Akira Miyata, Masayuki Kashima, Hiroshi Yokomizo

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Preoperative characteristics of living kidney donors are commonly considered during donor selection and postoperative follow-up. However, the impact of preoperative uric acid (UA) levels is poorly documented. The aim of this study was to evaluate the association between preoperative serum UA levels and post-donation long-term events and renal function.

Methods

This was a single-center retrospective analysis of 183 living kidney donors. The donors were divided into high (≥5.5 mg/dl) and low (< 5.5 mg/dl) UA groups. We analyzed the relationship between preoperative UA levels and postoperative estimated glomerular filtration rate (eGFR), as well as adverse events (cardiovascular events and additional prescriptions for hypertension, gout, dyslipidemia, and diabetes mellitus), over 5 years after donation.

Results

In total, 44 donors experienced 52 adverse events over 5 years. The incidence of adverse events within 5 years was significantly higher in the high UA group than in the low UA group (50% vs. 24%, p = 0.003); this was true even after the exclusion of hyperuricemia-related events (p = 0.047). UA emerged as an independent risk factor for adverse events (p = 0.012). Donors with higher UA levels had lower eGFRs after donation, whereas body mass index, hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol did not have any impact on the eGFR.

Conclusions

The findings suggest that preoperative UA levels should be considered during donor selection and postoperative follow-up.
Literature
1.
Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, et al. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020;20 Suppl s1:20–130.
2.
Kramer A, Pippias M, Noordzij M, Stel VS, Andrusev AM, Aparicio-Madre MI, et al. The European renal association - European Dialysis and transplant association (ERA-EDTA) registry annual report 2016: a summary. Clin Kidney J. 2019;12(5):702–20.PubMedPubMedCentralCrossRef
3.
Fahmy LM, Massie AB, Muzaale AD, Bagnasco SM, Orandi BJ, Alejo JL, et al. Long-term renal function in living kidney donors who had histological abnormalities at donation. Transplantation. 2016;100(6):1294–8.PubMedPubMedCentralCrossRef
4.
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374(5):411–21.PubMedCrossRef
5.
Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, et al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162–7.PubMedCrossRef
6.
Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, et al. Risk of end-stage renal disease following live kidney donation. Jama. 2014;311(6):579–86.PubMedPubMedCentralCrossRef
7.
Delmonico F. A report of the Amsterdam forum on the Care of the Live Kidney Donor: data and medical guidelines. Transplantation. 2005;79(6 Suppl):S53–66.PubMed
8.
Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017;101(8S Suppl 1):S1-s109.
9.
Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226–31.PubMedCrossRef
10.
Romi MM, Arfian N, Tranggono U, Setyaningsih WAW, Sari DCR. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. BMC Nephrol. 2017;18(1):326.PubMedPubMedCentralCrossRef
11.
Zhu DD, Wang YZ, Zou C, She XP, Zheng Z. The role of uric acid in the pathogenesis of diabetic retinopathy based on notch pathway. Biochem Biophys Res Commun. 2018;503(2):921–9.PubMedCrossRef
12.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–97.PubMedCrossRef
13.
Ho WJ, Tsai WP, Yu KH, Tsay PK, Wang CL, Hsu TS, et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology (Oxford). 2010;49(10):1929–34.CrossRef
14.
Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96(11):1576–8.PubMedCrossRef
15.
Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T, et al. Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens. 2011;24(7):770–4.PubMedCrossRef
16.
Otani N, Toyoda S, Sakuma M, Hayashi K, Ouchi M, Fujita T, et al. Effects of uric acid on vascular endothelial function from bedside to bench. Hypertens Res. 2018;41(11):923–31.PubMedCrossRef
17.
Matsukuma Y, Masutani K, Tanaka S, Tsuchimoto A, Haruyama N, Okabe Y, et al. Association between serum uric acid level and renal arteriolar hyalinization in individuals without chronic kidney disease. Atherosclerosis. 2017;266:121–7.PubMedCrossRef
18.
Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36(1):43–9.PubMedCrossRef
19.
Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–13.PubMedCrossRef
20.
21.
Kim K, Go S, Son HE, Ryu JY, Lee H, Heo NJ, et al. Association between serum uric acid level and ESRD or death in a Korean population. J Korean Med Sci. 2020;35(28):e254.PubMedPubMedCentralCrossRef
22.
Zhang W, Iso H, Murakami Y, Miura K, Nagai M, Sugiyama D, et al. Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. J Atheroscler Thromb. 2016;23(6):692–703.PubMedPubMedCentralCrossRef
23.
Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33(4):298–304.PubMedPubMedCentralCrossRef
24.
Dahle DO, Jenssen T, Holdaas H, Asberg A, Soveri I, Holme I, et al. Uric acid and clinical correlates of endothelial function in kidney transplant recipients. Clin Transpl. 2014;28(10):1167–76.CrossRef
25.
Lam NN, Garg AX, Segev DL, Schnitzler MA, Xiao H, Axelrod D, et al. Gout after living kidney donation: correlations with demographic traits and renal complications. Am J Nephrol. 2015;41(3):231–40.PubMedCrossRef
26.
Kulah E. Pretransplant uric acid levels may be predictive for prognosis of renal transplant donors. Ren Fail. 2016;38(4):487–92.PubMedCrossRef
27.
Cho A, Lee JE, Jang HR, Huh W, Kim DJ, Oh HY, et al. Association between pre-donation serum uric acid concentration and change in renal function after living kidney donation in women. Intern Med J. 2014;44(12a):1217–22.PubMedCrossRef
28.
Bravo RC, Gamo MB, Lee HH, Yoon YE, Han WK. Investigating serum uric acid as a risk factor in the development of delayed renal recovery in living kidney donors. Transplant Proc. 2017;49(5):930–4.PubMedCrossRef
29.
Nishida S, Hidaka Y, Toyoda M, Kinoshita K, Tanaka K, Kawabata C, et al. Factors related to suboptimal recovery of renal function after living donor nephrectomy: a retrospective study. BMC Nephrol. 2019;20(1):403.PubMedPubMedCentralCrossRef
30.
Brombo G, Bonetti F, Volpato S, Morieri ML, Napoli E, Bandinelli S, et al. Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study. Nutr Metab Cardiovasc Dis. 2019;29(10):1061–7.PubMedPubMedCentralCrossRef
31.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.
32.
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61.
33.
Kuwabara M, Hisatome I, Niwa K, Bjornstad P, Roncal-Jimenez CA, Andres-Hernando A, et al. The Optimal Range of Serum Uric Acid for Cardiometabolic Diseases: A 5-Year Japanese Cohort Study. J Clin Med. 2020;9(4).
34.
Qaseem A, Harris RP, Forciea MA. Management of Acute and Recurrent Gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58–68.PubMedCrossRef
35.
Qaseem A, McLean RM, Starkey M, Forciea MA. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):52–7.PubMedCrossRef
36.
Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–29.PubMedCrossRef
37.
Morozumi K. Clinical practice guidelines for renal transplant donors and recipients in Japan. Japanese J Transplantation. 2014;49(6):410–6.
38.
Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;3(1):39–40.PubMedPubMedCentralCrossRef
39.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.PubMedCrossRef
40.
Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12(12):1500–24.CrossRefPubMed
41.
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41(6):1341–5.PubMedCrossRef
42.
Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK, et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension. 2003;42(6):1144–9.PubMedCrossRef
43.
Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159–66.PubMedCrossRef
44.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMedCrossRef
45.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Jama. 2001;286(4):421–6.PubMedCrossRef
46.
Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26(4):670–5.PubMedCrossRef
47.
Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084–91.PubMed
48.
49.
Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012;14(2):179–88.PubMedCrossRef
50.
Kasiske BL, Anderson-Haag T, Ibrahim HN, Pesavento TE, Weir MR, Nogueira JM, et al. A prospective controlled study of kidney donors: baseline and 6-month follow-up. Am J Kidney Dis. 2013;62(3):577–86.PubMedPubMedCentralCrossRef
51.
Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10.CrossRef
52.
Talaat KM, El-sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435–40.PubMedCrossRef
53.
Giacomello A, Di Sciascio N, Quaratino CP. Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism. 1997;46(9):1085–9.PubMedCrossRef
54.
Chen S, Yang H, Chen Y, Wang J, Xu L, Miao M, et al. Association between serum uric acid levels and dyslipidemia in Chinese adults: a cross-sectional study and further meta-analysis. Medicine (Baltimore). 2020;99(11):e19088.CrossRef
55.
Tatar E, Karataş M, Kılıç M, Tercan IC, Okut G, Usoğlu B, et al. Onset of hypertension in living kidney donors after donor nephrectomy: our 20 years of experience. Exp Clin Transplant. 2019;17(Suppl 1):156–8.PubMedCrossRef
56.
57.
Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259.PubMedPubMedCentralCrossRef
58.
Kuwabara M, Kuwabara R, Hisatome I, Niwa K, Roncal-Jimenez CA, Bjornstad P, et al. "metabolically healthy" obesity and Hyperuricemia increase risk for hypertension and diabetes: 5-year Japanese cohort study. Obesity (Silver Spring). 2017;25(11):1997–2008.CrossRef
59.
Karatas M, Tatar E, Simsek C, Yıldırım AM, Uslu A. The relationship between serum uric acid levels and development of obesity in living kidney donors after donor nephrectomy. Eur J Clin Invest. 2021:e13507.
60.
Yelken B, Caliskan Y, Gorgulu N, Altun I, Yilmaz A, Yazici H, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol. 2012;77(4):275–82.PubMedCrossRef
61.
Okamoto M, Suzuki T, Fujiki M, Nobori S, Ushigome H, Sakamoto S, et al. The consequences for live kidney donors with preexisting glucose intolerance without diabetic complication: analysis at a single Japanese center. Transplantation. 2010;89(11):1391–5.PubMedCrossRef
62.
Chandran S, Masharani U, Webber AB, Wojciechowski DM. Prediabetic living kidney donors have preserved kidney function at 10 years after donation. Transplantation. 2014;97(7):748–54.PubMedCrossRef
63.
Chin R, Miyazaki S. Criteria of obesity and obesity disease in Japan. Nihon Rinsho. 2009;67(2):297–300.PubMed
64.
Sasazuki S, Inoue M, Tsuji I, Sugawara Y, Tamakoshi A, Matsuo K, et al. Body mass index and mortality from all causes and major causes in Japanese: results of a pooled analysis of 7 large-scale cohort studies. J Epidemiol. 2011;21(6):417–30.PubMedPubMedCentralCrossRef
65.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.PubMed
66.
Group TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef
67.
Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25(9):846–984.PubMedPubMedCentralCrossRef
68.
Transplantation JSfCRTTJSf. Annual Progress report from the Japanese renal transplant registry: number of renal transplantations in 2018 and follow-up survey. Japanese J Transplantation. 2019;54(2–3):61–80.
69.
70.
Henderson ML, Thomas AG, Shaffer A, Massie AB, Luo X, Holscher CM, et al. The National Landscape of living kidney donor follow-up in the United States. Am J Transplant. 2017;17(12):3131–40.PubMedPubMedCentralCrossRef
71.
Chen J, Bhattacharya S, Sirota M, Laiudompitak S, Schaefer H, Thomson E, et al. Assessment of Postdonation outcomes in US living kidney donors using publicly available data sets. JAMA Netw Open. 2019;2(4):e191851.PubMedPubMedCentralCrossRef
Metadata
Title
Long-term impact of baseline serum uric acid levels on living kidney donors: a retrospective study
Authors
Kosuke Tanaka
Shigeyoshi Yamanaga
Yuji Hidaka
Sho Nishida
Kohei Kinoshita
Akari Kaba
Toshinori Ishizuka
Satoshi Hamanoue
Kenji Okumura
Chiaki Kawabata
Mariko Toyoda
Akira Miyata
Masayuki Kashima
Hiroshi Yokomizo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02295-0

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue

Case report

C3 glomerulonephritis associated with ANCA positivity: a case report

Case report

An anastomosing hemangioma mimicking a renal cell carcinoma in a kidney transplant recipient: a case report

Research

Impact of AKI care bundles on kidney and patient outcomes in hospitalized patients: a systematic review and meta-analysis

Correction

Correction to: Hemolytic uremic syndrome caused by sea anemone sting: a case report

Research

Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell

Research article

Reliability and validity of the Persian version of 5-D itching scale among patients with chronic kidney disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits